270
Views
0
CrossRef citations to date
0
Altmetric
CLINICAL TRIAL REPORT

Subconjunctival Sirolimus-Loaded Liposomes for the Treatment of Moderate-to-Severe Dry Eye Disease

ORCID Icon, ORCID Icon, ORCID Icon, , , , , , , ORCID Icon & ORCID Icon show all
Pages 1295-1305 | Received 24 Jan 2023, Accepted 20 Apr 2023, Published online: 05 May 2023

References

  • Stapleton F, Alves M, Bunya VY, et al. TFOS DEWSII Epidemiology Report. Ocul Surf. 2017;15:334–365. doi:10.1016/j.jtos.2017.05.003
  • Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15:575–628. doi:10.1016/j.jtos.2017.05.006
  • Both T, Dalm VA, van Hagen PM, et al. Reviewing primary Sjögren’s syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment. Int J Med Sci. 2017;14:191–200. doi:10.7150/ijms.17718
  • Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438–510. doi:10.1016/j.jtos.2017.05.011
  • Kuklinski E, Asbell PA. Sjogren’s syndrome from the perspective of ophthalmology. Clin Immunol. 2017;182:55–61. doi:10.1016/j.clim.2017.04.017
  • Foulks GN, Forstot SL, Donshik PC, et al. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf. 2015;13:118–132. doi:10.1016/j.jtos.2014.12.001
  • Shah M, Edman MC, Reddy Janga S, et al. Rapamycin eye drops suppress lacrimal gland inflammation in a murine model of Sjögren’s syndrome. Invest Ophthalmol Vis Sci. 2017;58:372–385. doi:10.1167/iovs.16-19159
  • Zaza G, Granata S, Caletti C, et al. mTOR inhibition role in cellular mechanisms. Transplantation. 2018;102:S3–S16. doi:10.1097/TP.0000000000001806
  • Bertelmann E, Player U. Immunomodulatory therapy in ophthalmology – is there a place for topical application? Ophthalmologica. 2004;218:359–367. doi:10.1159/000080937
  • Wang S, Wang M, Liu Y, et al. Effect of rapamycin microspheres in Sjögren syndrome dry eye: preparation and outcomes. Ocul Immunol Inflamm. 2018;1:1–8. doi:10.1080/09273948.2018.1527369
  • Douglas LC, Yi NY, Davis JL, et al. Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses. J Vet Pharmacol Ther. 2008;31:511–516. doi:10.1111/j.1365-2885.2008.00986.x
  • Linares-Alba MA, Gómez-Guajardo MB, Fonzar JF, et al. Preformulation studies of a liposomal formulation containing sirolimus for the treatment of dry eye disease. J Ocul Pharmacol Ther. 2016;32:11–22. doi:10.1089/jop.2015.0032
  • Nguyen QD, Merrill PT, Sepah YJ, et al. Intravitreal sirolimus for the treatment of noninfectious uveitis: evolution through preclinical and clinical studies. Ophthalmology. 2018;125:1984–1993. doi:10.1016/j.ophtha.2018.06.015
  • Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615–621. doi:10.1001/archopht.118.5.615
  • Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21:221–232.
  • Baudouin C, Aragona P, Van Setten G, et al. Diagnosing the severity of dry eye: a clear and practical algorithm. Br J Ophthalmol. 2014;98:1168–1176. doi:10.1136/bjophthalmol-2013-304619
  • Aragona P, Aguennouz M, Rania L, et al. Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease. Ophthalmology. 2015;122:62–71. doi:10.1016/j.ophtha.2014.07.048
  • Schargus M, Ivanova S, Kakkassery V, et al. Correlation of tear film osmolarity and 2 different MMP-9 tests with common dry eye test in a cohort of non-dry eye patients. Cornea. 2015;34:739–744. doi:10.1097/ICO.0000000000000449